In a development that could reshape first‑line therapy for a distinct group of lung‑cancer patients, AstraZeneca and China‑based Hutchmed announced on Tuesday that their combined regimen of Tagrisso and Orpathys markedly improved progression‑free survival in a late‑stage clinical trial.
Trial design and patient population
The study enrolled patients with advanced non‑small cell lung cancer (NSCLC) whose tumors carry EGFR mutations and exhibit moderate to high levels of the MET protein marker. All participants were treatment‑naïve, meaning they had not received prior therapy for their disease.
Key findings
When given together early in the treatment course, the Tagrisso‑Orpathys combination extended the time patients lived without disease progression compared with Tagrisso alone, which is currently the standard first‑line option for this genetic subtype. The companies also reported encouraging signals in overall survival, a critical secondary endpoint.
“By combining Orpathys with Tagrisso, we have observed a clear clinical benefit that could reshape primary treatment strategy for this distinct patient population,” said Dr. Yi‑Long Wu, the trial’s leading principal investigator.
Implications for patients and the industry
If these results are confirmed in subsequent confirmatory studies, physicians may have a new, more effective option for patients whose cancers are driven by both EGFR mutations and MET amplification. Such an advance aligns with AstraZeneca’s broader focus on oncology, a segment that now accounts for nearly half of the company’s revenue.
Orpathys, still under development with Hutchmed, represents the Chinese firm’s growing role in global oncology research. The partnership underscores a trend of cross‑border collaborations aimed at accelerating drug development and expanding access to innovative therapies.
Looking ahead
AstraZeneca has set an ambitious target of $80 billion in annual sales by 2030, and successful oncology launches are central to that goal. Both companies indicated that they will continue to monitor safety and efficacy data as the trial progresses, with plans to seek regulatory approval if the outcomes remain favorable.
Patients, families, and healthcare providers are encouraged to stay informed about emerging treatment options, especially those that may offer longer disease control and improved quality of life.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
